An ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.
Pancreatic ductal adenocarcinoma is a disease marked by high rates of mortality, with only about 7% of patients surviving 5 years after diagnosis. Here, the authors present a demonstrative case and review the available data on hereditary and familial PDAC.
Panelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.
This article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
The panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.
With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.
Comprehensive cancer centers in Chicago and Atlanta earn national distinction as top performers in patient experience.
Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS; NCT04365374)
Mehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Misako Nagasaka, MD, PhD, summarizes the key takeaways: proactive AE management, CNS vigilance, and strategic sequencing as hallmarks of modern care for EGFR-mutant NSCLC.
Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.
Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.
Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.